Why the study?
Does losartan improve insulin sensitivity compared to atenolol in nondiabetic hypertensive patients?
Does losartan improve insulin sensitivity compared to atenolol in nondiabetic hypertensive patients?
Losartan improves insulin sensitivity in nondiabetic hypertensive patients, whereas atenolol worsens it, highlighting the metabolic advantages of ARBs over traditional beta-blockers.
No takes yet. Share an insight, caveat, or question.
Favors losartan over atenolol to preserve insulin sensitivity in nondiabetic hypertension; confirms ARB metabolic advantages versus beta-blockers.
Bharati et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: